In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster Session 3: Chronic Heart Failure – Pathophysiology and Mechanisms
Session

Event : Heart Failure 2018

Topic : Other

  • Session type : Poster Session
  • Date : 28 May 2018
  • Time : 08:30 - 18:00

44 presentations in this session

Relationship of circulating plasma levels of D-Dimer and outcome in patients with heart failure: findings from BIOSTAT-CHF

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : P Pellicori (Glasgow,GB)

Impact of left ventricular assist device implantation on right and left ventricular volumes and functions

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : S Cazalbou (Toulouse,FR)

The effect of standard treatment of acute decompensation of heart failure at the concentration of omega-3 and omega-6 polyunsaturated fatty acids in whole blood

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Zaplatina (Saint-Petersburg,RU)

Mortality from cardiovascular diseases among US cancer survivors

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : K Sturgeon (Norristown,US)

Low body mass index and arterial hypotension as early predictors of cardiotoxicity in patients with HER2 + breast cancer

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : F Ageev (Moscow,RU)

Routine use of global longitudinal strain among active breast cancer patients: A Cardio-Oncology registry

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Laufer-Perl (Tel Aviv,IL)

Dispersion of ventricular repolarization in men treated by hormone therapy for advanced prostatic cancer.

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : ACD Gheorghe (Bucharest,RO)

The use of myocardial deformation imaging to predict cardio toxicity in breast cancer treated with trastuzumab

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : C Yousfi (Sfax,TN)

Long-term follow up of acute heart failure patients underwent levosimendan infusion: identification of responders and non responders by using hlm classification

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Pucci (San Nicola La Strada,IT)

Haemodynamic profiles in type 2 pulmonary hypertension influence response to phosphodiesterase-5 inhibitors

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : P Alves (Coimbra,PT)

Mid-range ejection fraction: a grey zone in heart failure?

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : CL Gonzalez (Ciudad Autonoma De Buenos Aire,AR)

Ventriculoatrial remodeling in patients with recurrent atrial fibrillation and diastolic dysfunction: does gender matter?

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : Z Kobalava (Moscow,RU)

How about heart failure with reduced or preserved diastolic function?

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : J Sousa (Coimbra,PT)

Abnormally elevated left-ventricular filling pressure as a prognostic factor in an Advanced Heart Failure Unit

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : G Alonso Salinas (Madrid,ES)

Left ventricle remodeling, blood pressure profile and endothelial dysfunction in hypertensive patients with chronic heart failure

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : N Demikhova (Sumy,UA)

Relationship between parathyroid hormone and cardiac function and congestion in chronic heart failure: a prospective cohort study

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : L Kattnig (Graz,AT)

Total Left Atrial Emptying Fraction as a novel prognostic marker in HFrEF patients with significant functional mitral regurgitation

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : G Palmiero (Gricignano,IT)

Serum calcium, phosphate and parathormone homeostasis in patients with heart failure with reduced ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : E Sawicka (Bialystok,PL)

Design of the EMPERIAL-reduced trial of empagliflozin in patients with chronic heart failure with reduced ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : W Abraham (Columbus,US)

Changes of arterial function in patients with reduced left ventricular systolic function

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : KH Park (Anyang,KR)

Statins in non-ischemic heart failure - friend or foe?

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : J Sousa (Coimbra,PT)

Effect of Low-Dose Dopamine on Depression of Patients with Heart Failure in Coronary Intensive Unit

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : T Kivrak (Elazig,TR)

Prognostic impact of neurohormonal blockade in patients with an acute coronary syndrome and mid-range ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : P Azevedo (Faro,PT)

Urine biomarkers as determinants of poor outcomes in patients with acute kidney injury and heart failure with mid-range ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Klimenko (Moscow,RU)

Clinical characteristics and biomarkers in the patients with different phenotypes of heart failure

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : O Timakov (Odessa,UA)

Characteristics of obese patients with heart failure with mid-range ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Dadarlat (Cluj Napoca,RO)

Profile and differential management of patients with a mid-range ejection fraction compared to patients with reduced ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : D Enriquez Vazquez (Lugo,ES)

Genetic determination of myocardial mechanics: towards a deeper understanding of heart failure with preserved ejection fraction?

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Kovacs (Budapest,HU)

Differences in patient reported outcome in women and men with HFpEF

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : U Ljung Faxen (Bromma,SE)

Left atrial function, volume and compliance in patients with HFpEF

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : G Bajraktari (Prishtina,XK)

The dynamics of galectin-3 in patients with heart failure and preserved ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : Y Kushnir (Dnipropetrovsk,UA)

The level of uric acid in patients with heart failure with preserved ejection fraction depending on age

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : Y Kushnir (Dnipropetrovsk,UA)

Role of vascular endothelial growth factor-A in left ventricle remodeling and diastolic dysfunction in patients with heart failure

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : D Shorikova (Chernivtsy,UA)

Diastolic dysfunction grades stratify patients on chronic hemodialysis therapy

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : J Malik (Prague,CZ)

Hepatocardiac relations in patients with heart failure and diabetes mellitus.

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : I Knyazkova (Kharkov,UA)

Single centre audit of experience in tallaght hospital among patients with chronic heart failure and iron deficiency anemia (ida).

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : W Ashram (Dublin 18,IE)

Paulus criteria are valuable for predicting outcome in patients with asymptomatic diastolic dysfunction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Bobenko (Berlin,DE)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are